TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06104228: 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Sponsor: Bastiaan Driehuys · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,988,000

Rescue Site Savings

+$1,958,800

Unlock Full NCT06104228 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06104228 Rescue Dossier →